Cell Therapy for Cartilage Regeneration Gets a Boost With Hyaluronic Acid Enriched Chondrocytes in a 3D Tissue Engineering Platform
8.3.2021 11:20:00 EET | Business Wire | Press release
Regenerative therapy to treat knee joint damages gets a boost with a breakthrough technology of growing ideal type of cartilage cells including chondroprogenitors and mesenchymal stem cells enriched with hyaluronic acid (HA), reported by Dr Shojiro Katoh, President, Edogawa Hospital in “The KNEE” journal (https://doi.org/10.1016/j.knee.2021.02.019). Edogawa Evolutionary Laboratory of Science (EELS) researchers accomplished this feat using a 3D tissue engineering scaffold, without externally added HA or growth factors. They hope this technology will improvise the clinical outcome of Autologous Chondrocyte Implantation (ACI) and Matrix Assisted Chondrocyte Implantation (MACI) treatments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210308005305/en/
Edogawa Hospital team that accomplished a novel feat of regenerating osteoarthritis affected knee cartilage tissue through tissue engineering into clinically transplant-worthy chondrocytes enriched with hyaluronic acid, expressing chondroprogenitors; Sitting L>R: Dr. Shojiro Katoh (President), Dr. Masahiro Katoh (Chairman), Mr. Ryuzaburo Katoh (Director); Standing L>R; Other members of the team: Ms. Takako Fujisaki, Ms. Ayumi Mitsuhashi & Ms. Junko Tomioka. (Photo: Business Wire)
Regenerative medicine applications for articular cartilage repair require growing chondrocytes taken from patients’ own joint, in the lab, followed by transplantation to the disease affected portion, enable them restore, replace, rejuvenate or regenerate the cartilage in ACI or MACI procedures, practiced by orthopedicians and arthroscopy surgeons worldwide. The lab environment makes the chondrocytes, many a time, grow as fibrocartilage, whereas, hyaline cartilage is the ideal type of tissue required, which contributes to weight bearing function of the joint. Having proven hyaline cartilage growth in vitro (https://doi.org/10.1016/j.reth.2020.03.006) and their in vivo efficacy (https://doi.org/10.1016/j.jor.2017.01.003), EELS team has now proven that stem cell like progenitors and mesenchymal stem cells residing in the human cartilage could be grown without artificial reprogramming or animal proteins or feeder layers (https://doi.org/10.1016/j.jor.2021.01.005).
Hyaluranon (HA) in the matrix is essential for homeostasis of cartilage, which is injected to treat cartilage damages in clinics and in the lab, added from external sources to support chondrocyte culture. On the contrary, Dr Katoh`s team used a polymer scaffold that retains chondrocyte secreted HA to enhance their growth as a tissue, yielding higher HA content. This is another milestone in regenerative medicine, as it produces chondrocytes that are most suitable for clinical transplant with potentials for better healing and value addition to existing ACI and MACI procedures, after relevant clinical validation.
Further studies on miRNA-140, another essential cartilage component and the technology’s anti-aging capabilities are underway to address debilitating joint diseases affecting millions worldwide in this method termed “EELS-TALC”, (Enriched with Essentials and Lapped in Scaffold, Transplant-suitable Autologous Leveraged Chondrocytes) in collaboration among EELS, JBM Inc and GN Corporation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005305/en/
Contact information
Samuel JK Abraham
info@gncorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves Erbitux ® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation14.7.2026 12:00:00 EEST | Press release
Merck, a leading global science and technology company, today announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) — both in first-line treatment in combination with FOLFOX (BREAKWATER regimen) and for patients who have received prior systemic therapy (BEACON regimen). The first-line approval is based on results from the Phase 3 BREAKWATER trial, which showed that the cetuximab–encorafenib–FOLFOX combination delivered statistically significant and clinically meaningful improvements in the dual primary endpoints of objective response rate (ORR) and PFS, as well as a significant overall survival benefit — reducing the risk of death by 51% versus chemotherapy with or without bevacizumab. ”The approval of Erbitux in combination with encorafenib and FOLFOX marks an important milestone for patients wit
Nordic Firms Seek Green, Sovereign AI Infrastructure14.7.2026 12:00:00 EEST | Press release
Nordic enterprises are adopting private and hybrid cloud infrastructure that combines AI-ready capacity, local residency and low-carbon operations as high-performance workloads and geopolitical risk reshape IT strategies, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The 2026 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Nordics finds that the region is evolving from a hosting destination into a backbone for European data processing. Enterprises are using the Nordics’ renewable energy and natural cooling to support cloud strategies that balance large scale with environmental consciousness and compliance with data sovereignty regulations. “Nordic enterprises are connecting infrastructure decisions to resilience, data control and sustainability rather than treating cloud as a capacity purchase,” said Susanta Dey, director, ISG EMEA Cloud and
Swiss Pension Funds Increase Commitments to Record Infrastructure Equity Fund to EUR 1.23 Billion14.7.2026 10:58:00 EEST | Press release
Record Asset Management GmbH (RAM), subsidiary of London-listed Record plc (Record Financial Group), today announced that its Infrastructure Equity fund has attracted EUR 160 million of additional capital from Swiss pension funds, increasing total commitments to approximately EUR 1.23 billion. Capital deployment continues to progress in line with expectations, with more than one-third of the fund’s initial capital now deployed or committed to investments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713541233/en/ RAM manages a dedicated infrastructure co-investment vehicle in partnership with APG, the pension asset manager of ABP, providing Swiss pension funds with access to large-scale infrastructure equity investments alongside APG’s pension fund partners. RAM is the European asset management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of in
Samsung Becomes a Sisvel Wi-Fi Multimode Pool Licensee and Licensor14.7.2026 10:09:00 EEST | Press release
Samsung Electronics has signed up as a licensee of the Sisvel Wi-Fi Multimode pool and has also become a licensor under the programme. The decision by the South Korean company - a global R&D powerhouse and among the world’s top smartphone vendors, as well as a leader in many other electronic product categories - not only confirms the Sisvel Wi-Fi Multimode pool as a recognised solution provider for parties seeking to derisk Wi-Fi implementation but also considerably expands the scope of the programme’s patent offering. Since it was publicly launched in January 2026, ASUS, Hewlett Packard Enterprise, Microsoft and Sony Group Corporation have become licensees of the Sisvel Wi-Fi Multimode pool. There are also five licensor/licensee companies: Huawei, Panasonic, Philips, Samsung Electronics and ZTE. The other licensors are KPN, Mitsubishi Electric, Orange, Aegis 11 SA, SK Telecom and Wilus. The agreement announced today ends litigation in the Eastern District of Texas between Samsung Elec
Wolters Kluwer Integrates Legal Intelligence Platform With Libra Legal AI Workspace in the Netherlands14.7.2026 10:00:00 EEST | Press release
Wolters Kluwer Legal & Regulatory today announced the integration of its Legal Intelligence multi-content-provider platform with the Libra by Wolters Kluwer AI workspace in the Netherlands. Dutch legal professionals will now be able to access more than 5000 additional pieces of expert legal content from Wolters Kluwer and third-party content providers as well as public sources in addition to the existing content offerings in Libra. “By bringing Legal Intelligence into Libra, we move beyond traditional search to truly integrated, AI-driven workflows,” said Rimco Spanjer, Vice President & Managing Director, Wolters Kluwer Legal & Regulatory Benelux. “Combining our authoritative content with trusted third-party sources in one AI workspace enables legal professionals to work smarter every day.” The integration will include trusted legal content from Kluwer Law International, Ars Aequi, Amsterdam University Press, Celsus Juridische uitgerij, Iustitia Scripta, M.A.D.Lex, MOC Uitgeverij, NL-F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom